Home » Topics » Regulatory » EMA

EMA
RSS

CHMP recommends approval of Tasigna in E.U. as first-line therapy for Ph+ CML

Sep. 28, 2010

FDA and EMA to review vandetanib for advanced medullary thyroid cancer

Sep. 27, 2010

EMA updates nevirapine label for patients with HIV-1 infection

Sep. 21, 2010

Novartis Europharm withdraws Rasival MAA for essential hypertension

Sep. 21, 2010

GSK investigates reports of narcolepsy following Pandemrix vaccination

Sep. 6, 2010

MSD's Sycrest approved in Europe for biopolar disorder

Sep. 3, 2010

FDA approves Bionovo's CMC plan for Menerba

Aug. 31, 2010

EMA investigates potential relationship between Pandemrix and narcolepsy

Aug. 30, 2010

European Commission updates license for Cervarix HPV vaccine

Aug. 30, 2010

Shire's VPRIV approved in Europe for type 1 Gaucher's disease

Aug. 27, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...